Ataraxis AI, a NYC-based AI precision medicine company, raised $4M in Seed funding.
The round was led by Giant Ventures and Obvious Ventures.
The company intends to use the funds to expand its partnerships to make its test available to as many patients as possible.
Led by CEO Jan Witowski, Ataraxis is an AI precision medicine company transforming cancer diagnostics and patient outcomes through artificial intelligence. To enable this new era of AI precision medicine, the company has developed Kestrel, a foundation AI model for digital pathology. The Kestrel model discovers novel features correlated with patient outcomes that are often more complex than what can be understood by human experts, including physicians, and span all disease types. Using these findings, Ataraxis can develop multi-modal diagnostic tests for any indication that continuously improve in accuracy, can be applied quickly to any clinical scenario, have a wide scope, and are delivered in a software-like manner. Its first clinically validated offering, Ataraxis Breast, is an AI-native prognostic/predictive test for breast cancer and provides greater accuracy than standard of care genomic assays. The test has initially been clinically validated in a multi-site study testing over 7,500 patients from 15 institutions across 3 continents, with plans for further validation.
FinSMEs
31/10/2024